CanSino Biologics Inc. (CASBF)
OTCMKTS · Delayed Price · Currency is USD
4.474
-0.271 (-5.71%)
At close: Jan 22, 2026
CanSino Biologics Employees
CanSino Biologics had 1,115 employees as of June 30, 2025. The number of employees increased by 10 or 0.90% since the number was reported on December 31, 2024.
Employees
1,115
Change
10
Growth
0.90%
Revenue / Employee
$123,537
Profits / Employee
-$18,055
Market Cap
1.64B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 1,115 | 10 | 0.90% |
| Dec 31, 2024 | 1,105 | -389 | -26.04% |
| Dec 31, 2023 | 1,494 | -797 | -34.79% |
| Dec 31, 2022 | 2,291 | 345 | 17.73% |
| Dec 31, 2021 | 1,946 | 1,517 | 353.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jushi Holdings | 1,234 |
| MariMed | 832 |
| Glass House Brands | 374 |
| Earth Science Tech | 76 |
| Elite Pharmaceuticals | 68 |
| Radnostix | 42 |
| Healthy Extracts | 2 |
CanSino Biologics News
- 3 days ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 10 months ago - CanSino Biologics CEO on earnings, business outlook, and international partnerships - CNBC
- 3 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire